HC Wainwright raises FY2026 earnings estimate for OPKO Health Inc.
What happened
Research analysts at HC Wainwright raised their full-year 2026 earnings per share estimate for OPKO Health Inc. Analyst Y. Chen now anticipates the biotechnology company will post earnings of ($0.18) per share, an improvement from the previous estimate of ($0.23) per share. HC Wainwright maintains a “Buy” rating on the stock.
From tickerreport.com
Why it matters
The improved financial outlook for OPKO Health Inc. could support the stability and value of the IP licensing agreement with Eli Lilly and Company. HC Wainwright currently holds a “Buy” rating on the company.
From tickerreport.com
Who's involved
- Y. ChenHC Wainwright analyst who raised the earnings estimate for OPKO Health Inc.
- Eli Lilly and CompanyCompany involved in an IP licensing agreement with OPKO Health Inc.
- EyePoint Pharmaceuticals (United Kingdom)Company whose market coverage is referenced in Y. Chen's research notes.
- OCSCompany with insufficient evidence to establish a relationship with Y. Chen.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Eli Lilly and CompanySpeculative
The stability and value of the IP licensing agreement could be supported by OPKO Health Inc.'s improved financial outlook.
Keep exploring
The entities involved
-
Y. Chen
researcher
Nothing else this week.